Arima Genomics touted results from its Aventa Hi‑C lymphoma assay that detected clinically significant gene fusions and structural rearrangements in FFPE lymphoma samples where FISH was inconclusive. The company argues Hi‑C 3D genomics preserves spatial proximity of fused genes and amplifies signals for rearrangement detection, enabling comprehensive, hypothesis‑free genome analysis that could streamline workflows currently dependent on targeted FISH panels and cytogenetic review. Arima is commercializing Hi‑C assays after a $22M Series C and acquisition of a clinical lab JV.